Pluri (PLUR) 8-K Submission of Matters to a Vote of Security Holders

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 22, 2013 (May 21, 2013)

PLURISTEM THERAPEUTICS INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada

(State or Other Jurisdiction of Incorporation)

001-31392	98-0351734
(Commission File Number)	(IRS Employer Identification No.)

MATAM Advanced Technology Park Building No. 5 Haifa, Israel	31905
(Address of Principal Executive Offices)	(Zip Code)

011 972 74 710 7171

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07.  Submission of Matters to a Vote of Security Holders.

Pluristem Therapeutics Inc. (the “Company”), held its annual meeting of stockholders on May 21, 2013. The results of the stockholder voting at the annual meeting are set forth below.

Stockholders voted on the matters set forth below:

Proposal No. 1 — Election of Directors

The stockholders elected the following individuals as directors of the Company to hold office until the next annual meeting of shareholders and until their successors shall have been duly elected and qualified.

Director Name	For		Against		Abstain		Broker Non-Votes
Zami Aberman		10,524,983		1,693,895		32,411		16,259,162
Israel Ben-Yoram		12,072,682		75,845		102,762		16,259,162
Isaac Braun		12,075,388		74,420		101,481		16,259,162
Mark Germain		12,057,290		92,518		101,481		16,259,162
Moria Kwiat		12,017,624		129,784		103,881		16,259,162
Hava Meretzki		12,004,820		170,707		75,762		16,259,162
Nachum Rosman		12,062,603		87,245		101,441		16,259,162
Doron Shorrer		12,041,363		118,197		91,729		16,259,162

Proposal No. 2 — Advisory Vote on the Compensation of our Named Executive Officers

For		Against		Abstain		Broker Non-Votes
	10,264,977		1,834,739		151,573		16,259,162

Proposal No. 3 — Advisory Vote on the Frequency of the Advisory Vote on Compensation of our Named Executive Officers

1 Year		2 Years		3 Years		Abstain		Broker Non-Votes
	3,296,595		7,492,304		1,109,624		352,766		16,259,162

Proposal No. 4 — Ratification of the Selection of Kost Forer Gabbay & Kasierer, a Member of Ernst & Young Global, as Independent Registered Public Accounting Firm of the Company for the Fiscal Year Ending June 30, 2013

For		Against		Abstain		Broker Non-Votes
	27,754,826		224,670		530,955	-

The results reported above are final voting results.

In accordance with the stockholder voting results, in which every “Two Years” received the highest number of votes cast on the frequency proposal, and our Board of Directors’ recommendation in the proxy statement for the 2013 annual meeting of stockholders, our Board of Directors has determined that future stockholder advisory (non-binding) votes on the compensation of our named executive officers will occur every two years. Accordingly, the next stockholder advisory (non-binding) vote on executive compensation will be held at our 2015 annual meeting of stockholders.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PLURISTEM THERAPEUTICS INC.
Date: May 22, 2013	By:	/s/ Yaky Yanay
	Name:	Yaky Yanay
	Title:	Executive Vice President, Chief Financial Officer and Secretary